Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 7, 2014, Pages 1371-1386

  Kim, Sang Gyun ^a   Jung, Hye Kyung ^b   Lee, Hang Lak ^c   Jang, Jae Young ^d   Lee, Hyuk ^e   Kim, Chan Gyoo ^h   Shin, Woon Geon ^f   Shin, Ein Soon ^g,i   Lee, Yong Chan ^e  

^a Seoul National University College of Medicine   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Hallym University College of Medicine   (South Korea)

^g Korean Academy of Medical Sciences   (South Korea)

^h National Cancer Center   (South Korea)

ⁱ Ajou University School of Medicine   (South Korea)

Author keywords

Adaptation; Diagnosis; Guideline; Helicobacter pylori; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATROPHIC GASTRITIS; BIOPSY; CANCER PREVENTION; CANCER SURGERY; CLINICAL PRACTICE; CONSENSUS; DATA EXTRACTION; DELPHI STUDY; DIAGNOSTIC TEST; DISEASE ERADICATION; DYSPEPSIA; ENDOSCOPIC SURGERY; EVALUATION STUDY; EVIDENCE BASED PRACTICE; FAMILY HISTORY; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTESTINE METAPLASIA; INVASIVE PROCEDURE; KOREA; LONG TERM CARE; LOW DRUG DOSE; MARGINAL ZONE LYMPHOMA; NON INVASIVE PROCEDURE; PEPTIC ULCER; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW (TOPIC); TREATMENT FAILURE; TREATMENT INDICATION; EVIDENCE BASED MEDICINE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIOLOGY; SOUTH KOREA;

EVIDENCE-BASED MEDICINE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; REPUBLIC OF KOREA;

EID: 84904364425     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12607     Document Type: Review

References (133)

1. Korean H. pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J. Gastroenterol. 1998; 32: 275-289.
2. Yim JY, Kim N, Choi SH etal. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007; 12: 333-340.
3. Kim JH, Kim HY, Kim NY etal. Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J. Gastroenterol. Hepatol. 2001; 16: 969-975.
4. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J. Gastroenterol. 2009; 54: 269-278.
5. Kim MS, Kim N, Kim SE etal. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter 2013; 18: 135-142.
6. Park B, Choi KS, Lee YY, Jun JK, Seo HG. Trends in cancer screening rates among Korean men and women: results from the Korean National Cancer Screening Survey (KNCSS), 2004-2011. Cancer Res. Treat. 2012; 44: 113-120.
7. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-353.
8. Chang WK, Kim HY, Kim DJ etal. Association between Helicobacter pylori infection and the risk of gastric cancer in the Korean population: prospective case-controlled study. J. Gastroenterol. 2001; 36: 816-822.
9. Cho SJ, Choi IJ, Kim CG etal. Helicobacter pylori seropositivity is associated with gastric cancer regardless of tumor subtype in Korea. Gut Liver 2010; 4: 466-474.
10. Kim N, Park RY, Cho SI etal. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J. Clin. Gastroenterol. 2008; 42: 448-454.
11. Fervers B, Remy-Stockinger M, Graham ID etal. Guideline adaptation: an appealing alternative to de novo guideline development. Ann. Intern. Med. 2008; 148: 563-564, author reply 564-565.
12. The ADAPTE Collaboration. ADAPTE framework. Cited 13 Jul 2010. Available from URL: http://www.adapte.org
13. Mahadeva S, Chia YC, Vinothini A, Mohazmi M, Goh KL. Cost-effectiveness and satisfaction with a Helicobacter pylori "test and treat" strategy compared with prompt endoscopy in young Asians with dyspepsia. Gut 2008; 57: 1214-1220.
14. Steering Committee for Clinical Practice Guideline. Adaptation Process for Developing Korean Clinical Practice Guideline, 1st edn. Seoul: Minister of Health & Welfare, Korean Academy of Medical Science, 2011.
15. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 2007; 102: 1808-1825.
16. Hunt R, Fallone C, van Zanten SV etal. Canadian Helicobacter Study Group Consensus Conference: update on the management of Helicobacter pylori-An evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can. J. Gastroenterol. 2004; 18: 547-554.
17. Schunemann HJ, Oxman AD, Brozek J etal. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-1110.
18. Kim SG, Jung HK, Lee HL etal. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J. Gastroenterol. 2013; 62: 3-26.
19. Kim JI, Kim SG, Kim N etal. Changing prevalence of upper gastrointestinal disease in 28893 Koreans from 1995 to 2005. Eur. J. Gastroenterol. Hepatol. 2009; 21: 787-793.
20. Leodolter A, Kulig M, Brasch H etal. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment. Pharmacol. Ther. 2001; 15: 1949-1958.
21. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144: 528-535.
22. Wotherspoon AC, Dogolioni C, Diss TC etal. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577.
23. Hong SS, Jung HY, Choi KD etal. A prospective analysis of low-grade gastric MALT lymphoma after Helicobacter pylori eradication. Helicobacter 2006; 11: 569-573.
24. Inagaki H, Nakamura T, Sugiyama T etal. Gastric MALT lymphoma are divided into three groups based on responsiveness to H. pylori eradication and detection of API2-MALT1 fusion. Am. J. Surg. Pathol. 2004; 28: 1560-1567.
25. Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J. Gastroenterol. 2010; 16: 2158-2162.
26. Asaka M, Kato M, Takahashi S etal. Guidelines for the management of Helicobacter pylori in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.
27. Uemura N, Mukai T, Okamoto S etal. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 639-642.
28. Nakagawa S, Asaka M, Kato M etal. Helicobacter pylori eradication and metachronous gastric cancer after endoscopic mucosal resection of early gastric cancer. Aliment. Pharmacol. Ther. 2006; 2: 214-218.
29. Fukase K, Kato M, Kikuchi S etal. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet 2008; 372: 392-397.
30. Maehata Y, Nakamura S, Fujisawa K etal. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest. Endosc. 2012; 75: 39-46.
31. Ekström AM, Held M, Hansson LE, Engstrand L, Nyrén O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121: 784-791.
32. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52: 6735-6740.
33. Uemura N, Okamoto S, Yamamoto S etal. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-789.
34. Ohata H, Kitauchi S, Yoshimura N etal. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer 2004; 109: 138-143.
35. Kim N, Park YS, Cho SI etal. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008; 13: 245-255.
36. Kim HJ, Choi BY, Byun TJ etal. The prevalence of atrophic gastritis and intestinal metaplasia according to gender, age and Helicobacter pylori infection in a rural population. J. Prev. Med. Public Health 2008; 41: 373-379.
37. van Grieken NC, Meijer GA, Kale I etal. Quantitative assessment of gastric antrum atrophy shows restitution to normal histology after Helicobacter pylori eradication. Digestion 2004; 69: 27-33.
38. Lu B, Chen MT, Fan YH, Liu Y, Meng LN. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J. Gastroenterol. 2005; 11: 6518-6520.
39. Malfertheiner P, Megraud F, O'Morain CA etal. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664.
40. Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998; 3: 236-240.
41. Wang J, Xu L, Shi R etal. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83: 253-260.
42. You WC, Brown LM, Zhang L etal. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J. Natl Cancer Inst. 2006; 98: 974-983.
43. Wong BC, Lam SK, Wong WM etal. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194.
44. Zanghieri G, Di Gregorio C, Sacchetti C etal. Familial occurrence of gastric cancer in the 2-year experience of 5a population-based registry. Cancer 1990; 66: 2047-2051.
45. Rokkas T, Sechopoulos P, Pistiolas D, Margantinis G, Koukoulis G. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur. J. Gastroenterol. Hepatol. 2010; 22: 1128-1133.
46. Chang YW, Han YS, Lee DK etal. Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients. Int. J. Cancer 2002; 101: 469-474.
47. Shin CM, Kim N, Yang HJ etal. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J. Clin. Gastroenterol. 2010; 44: 34-39.
48. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. Gut 2004; 53: 1758-1763.
49. Ford AC, Qume M, Moayyedi P etal. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005; 128: 1838-1844.
50. Jung HK, Keum BR, Jo YJ etal. Diagnosis of functional dyspepsia: a systematic review. Korean J. Gastroenterol. 2010; 55: 296-307.
51. Shin MH, Oh HK, Ahn YO. Ten year trend of cancer incidence in Seoul, Korea: 1993-2002. J. Prev. Med. Public Health 2008; 41: 92-99.
52. Moayyedi P. Helicobacter pylori test and treat strategy for young dyspeptic patients: new data. Gut 2002; 50 (Suppl. 4): iv47-50.
53. Blum AL, Talley NJ, O'Morain C etal. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N. Engl. J. Med. 1998; 339: 1875-1881.
54. McColl K, Murray L, El-Omar E etal. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N. Engl. J. Med. 1998; 339: 1869-1874.
55. Moayyedi P, Soo S, Deeks J etal. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst. Rev. 2006; (2)CD002096.
56. Mazzoleni LE, Sander GB, Francesconi CF etal. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch. Intern. Med. 2011; 171: 1929-1936.
57. Gwee KA, Teng L, Wong RK, Ho KY, Sutedja DS, Yeoh KG. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 2009; 21: 417-424.
58. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007; 12: 541-546.
59. Moayyedi P, Soo S, Deeks J etal. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000; 321: 659-664.
60. Kim SH, Hong DY, Kang PS etal. Community-based Helicobacter pylori screening and its effects on eradication in patients with dyspepsia. Korean J. Prev. Med. 2000; 33: 285-298.
61. Lee EJ, Gham CW, Park TW etal. The effect of Helicobacter pylori eradication on the improvement of the symptoms in patients with functional dyspepsia and peptic ulcer disease. Korean J. Med. 2006; 71: 141-148.
62. El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-691.
63. O'Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment. Pharmacol. Ther. 1999; 13: 117-127.
64. Vicari JJ, Peek RM, Falk GW etal. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-57.
65. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-1126.
66. Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am. J. Gastroenterol. 2010; 105: 1007-1013, quiz 1006, 1014.
67. Kim BC, Yoon YH, Jyung HS etal. Clinical characteristics of gastroesophageal reflux diseases and association with Helicobacter pylori infection. Korean J. Gastroenterol. 2006; 47: 363-369.
68. Chung SJ, Lim SH, Choi J etal. Helicobacter pylori serology inversely correlated with the risk and severity of reflux esophagitis in Helicobacter pylori endemic area: a matched case-control study of 5, 616 health check-up Koreans. J. Neurogastroenterol. Motil. 2011; 17: 267-273.
69. Kim N, Lee SW, Kim JI etal. Effect of Helicobacter pylori eradication on the development of reflux esophagitis and gastroesophageal reflux symptoms: a nationwide multi-center prospective study. Gut Liver 2011; 5: 437-446.
70. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 2002; 16: 163-173.
71. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
72. Chan FK, Ching J, Suen B etal. H. pylori eradication on the long-term incidence of recurrent ulcer bleeding in high-risk aspirin users: a 10-year prospective cohort study (abstr). Gastroenterology 2011; 140: S173-174.
73. Lai KC, Lam SK, Chu KM etal. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002; 346: 2033-2038.
74. Chan FK, Sung JJ, Chung SC etal. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-979.
75. Chan FL, To KF, Wu JC etal. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet 2002; 359: 9-13.
76. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther. 2005; 21: 1411-1418.
77. Hawkey CJ, Tulassay Z, Szczepanski L etal. Randomized controlled trial of Helicobacter pylori eradication on patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 1016-1021.
78. Franchini M, Veneri D. Helicobacter pylori infection and immune thrombocytopenic purpura. Haematologica 2003; 88: 1087-1091.
79. Kurtoglu E, Kayacetin E, Ugur A. Helicobacter pylori infection in patients with autoimmune thrombocytopenic purpura. World J. Gastroenterol. 2004; 10: 2113-2115.
80. Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2007; 60: 237-246.
81. Gisbert JP, Pajares JM. 13C-urea breath test in the diagnosis of Helicobacter pylori infection: a critical review. Aliment. Pharmacol. Ther. 2004; 20: 1001-1017.
82. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann. Intern. Med. 1998; 129: 547-550.
83. Gatta L, Vakil N, Ricci C etal. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am. J. Gastroenterol. 2004; 99: 823-829.
84. Choi J, Kim CH, Kim D etal. Prospective evaluation of a new stool antigen test for the detection of Helicobacter pylori, in comparison with histology, rapid urease test, (13)C-urea breath test, and serology. J. Gastroenterol. Hepatol. 2011; 26: 1053-1059.
85. Kim PS, Lee JW, Pai SH etal. Detection of Helicobacter pylori antigen in stool by enzyme immunoassay. Yonsei Med. J. 2002; 43: 7-13.
86. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am. J. Gastroenterol. 2006; 101: 1921-1930.
87. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am. J. Gastroenterol. 2006; 101: 848-863.
88. Kokkola A, Rautelin H, Puolakkainen P etal. Diagnosis of Helicobacter pylori infection in patients with atrophic gastritis: comparison of histology, 13C-urea breath test, and serology. Scand. J. Gastroenterol. 2000; 35: 138-141.
89. Adamsson I, Nord CE, Sjostedt S, Wikstrom B, Seensalu R. The value of different detection methods of Helicobacter pylori during treatment. J. Clin. Gastroenterol. 1998; 27: 138-142.
90. Roe IH, Lee MI, Kim JT etal. Comparison of Hp kit test and CLO test for the diagnosis of Helicobacter pylori infection. Korean J. Gastroenterol. 1999; 34: 448-454.
91. Laine L, Lewin DN, Naritoku W, Cohen H. Prospective comparison of H&E, Giemsa, and Genta stains for the diagnosis of Helicobacter pylori. Gastrointest. Endosc. 1997; 45: 463-467.
92. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 1996; 20: 1161-1181.
93. El-Zimaity HM. Accurate diagnosis of Helicobacter pylori with biopsy. Gastroenterol. Clin. North Am. 2000; 29: 863-869.
94. Kim CG, Choi IJ, Lee JY etal. Biopsy site for detecting Helicobacter pylori infection in patients with gastric cancer. J. Gastroenterol. Hepatol. 2009; 24: 469-474.
95. Satoh K, Kimura K, Taniguchi Y etal. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am. J. Gastroenterol. 1998; 93: 569-573.
96. Kim NY, Ko JJ, Ko YH etal. The detection rate of H. pylori and intestinal metaplasia in the antrum and in the body. Korean J. Gastrointest. Endosc. 1999; 19: 1-9.
97. Fock KM, Katelaris P, Sugano K etal. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009; 24: 1587-1600.
98. Gatta L, Ricci C, Tampieri A etal. Accuracy of breath tests using low doses of 13C-urea to diagnose Helicobacter pylori infection: a randomised controlled trial. Gut 2006; 55: 457-462.
99. Yang HR, Seo JK. Helicobacter pylori stool antigen (HpSA) tests in children before and after eradication therapy: comparison of rapid immunochromatographic assay and HpSA ELISA. Dig. Dis. Sci. 2008; 53: 2053-2058.
100. Kwon KT, Lee DS, Chung IK etal. The diagnostic validity of Helicobacter pylori stool antigen test in the pre- and post-eradication. Korean J. Gastroenterol. 2004; 44: 199-205.
101. Lee JY, Kim N, Song CH etal. Usefullness of PyloriTek test for Helicobacter pylori detection after eradication therapy. Korean J. Gastroenterol. 2000; 35: 170-177.
102. Lam SK, Talley NJ. Report of the 1997 Asia-Pacific Consensus Conference on the management of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 1998; 13: 1-12.
103. Huang JQ, Chiba N, Wilkinson J, Hunt RH. Which combination therapy can eradicate >90% Helicobacter pylori infection? A meta-analysis of amoxicillin, metronidazole, tetracycline and clarithromycin containing regimens. Gastroenterology 1997; 112: A19.
104. Malfertheiner P, Payerdorffer E, Diete U etal. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment. Pharmacol. Ther. 1999; 13: 703-712.
105. Wong BC, Chang FY, Abid S etal. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment. Pharmacol. Ther. 2000; 14: 1529-1535.
106. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob. Agents Chemother. 2004; 48: 4843-4847.
107. Kim BG, Lee DH, Ye BD etal. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007; 12: 31-35.
108. Fuccio L, Minardi ME, Zagari RM etal. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med. 2007; 147: 553-562.
109. Lee JW, Kim N, Kim JM etal. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013; 18: 206-214. doi:10.1111/hel.12031.
110. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment. Pharmacol. Ther. 2004; 20: 1071-1082.
111. Laine L, Hunt R, el-Zimaity H etal. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol. 2003; 98: 562-567.
112. Kim N, Kim JM, Kim CH etal. Institutional difference of antibiotics resistance of Helicobacter pylori strains in Korea. J. Clin. Gastroenterol. 2006; 40: 683-687.
113. Chung JW, Lee JH, Jung HY etal. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289-294.
114. Lee BH, Kim N, Hwang TJ etal. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45.
115. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int. J. Antimicrob. Agents 2006; 28: 6-13.
116. Kwon JH, Lee DH, Song BJ etal. Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study. Helicobacter 2010; 15: 148-153.
117. Choi HS, Chun HJ, Park SH etal. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J. Gastroenterol. 2012; 18: 2377-2382.
118. Chung JW, Jung YK, Kim YJ etal. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J. Gastroenterol. Hepatol. 2012; 27: 1675-1680.
119. Oh HS, Lee DH, Seo JY etal. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J. Gastroenterol. Hepatol. 2012; 27: 504-509.
120. Park HG, Jung MK, Jung JT etal. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. Aliment. Pharmacol. Ther. 2012; 35: 56-65.
121. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J. Clin. Gastroenterol. 2010; 44: 313-325.
122. De Francesco V, Margiotta M, Zullo A etal. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann. Intern. Med. 2006; 144: 94-100.
123. Gisbert JP, Calvet X. Non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment. Pharmacol. Ther. 2011; 34: 604-617.
124. Kim SY, Lee SW, Hyun JJ etal. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J. Clin. Gastroenterol. 2013; 47: 21-24.
125. Lim JH, Lee DH, Choi C etal. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 2013; 18: 180-186. doi:10.1111/hel.12034.
126. Magaret N, Burm M, Faigel D, Kelly C, Peterson W, Fennerty MB. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig. Dis. 2001; 19: 174-178.
127. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J. Antimicrob. Chemother. 2005; 56: 965-967.
128. Hwang TJ, Kim N, Kim HB etal. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J. Clin. Gastroenterol. 2010; 44: 536-543.
129. Perri F, Festa V, Clemente R etal. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol. 2001; 96: 58-62.
130. Jeong MH, Chung JW, Lee SJ etal. Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori. Korean J. Gastroenterol. 2012; 59: 401-406.
131. Lee YC, Lee SY, Pyo JH, Kwon DH, Rhee JC, Kim JJ. Isogenic variation of Helicobacter pylori strain resulting in heteroresistant antibacterial phenotypes in a single host in vivo. Helicobacter 2005; 10: 240-248.
132. National Committee for Clinical Laboratory Standards. Acceptable limits for quality control strains used to monitor accuracy of minimal inhibitory concentrations of fastidious organisms. In: Performance standards for antimicrobial susceptibility testing, 12th informational supplement, M100-S12, Vol. 22 no. 1 NCCLS 2002, Wayne, PA.
133. Woo HY, Park DI, Park H etal. Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens. Helicobacter 2009; 14: 22-28.